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Background: There is currently no validated strategy for the timing of renal replacement therapy (RRT) for acute
kidney injury (AKI) in the intensive care unit (ICU) when short-term life-threatening metabolic abnormalities are absent.
No adequately powered prospective randomized study has addressed this issue to date. As a result, significant practice
heterogeneity exists and may expose patients to either unnecessary hazardous procedures or undue delay in RRT.
Methods/design: This is a multicenter, prospective, randomized, open-label parallel-group clinical trial that compares the
effect of two RRT initiation strategies on overall survival of critically ill patients receiving intravenous catecholamines or
invasive mechanical ventilation and presenting with AKI classification stage 3 (KDIGO 2012). In the ‘early’ strategy, RRT is
initiated immediately. In the ‘delayed’ strategy, clinical and metabolic conditions are closely monitored and RRT is initiated
only when one or more events (severity criteria) occur, including: oliguria or anuria for more than 72 hours after
randomization, serum urea concentration >40 mmol/l, serum potassium concentration >6 mmol/l, serum potassium
concentration >5.5 mmol/l persisting despite medical treatment, arterial blood pH <7.15 in a context of pure metabolic
acidosis (PaCO2 < 35 mmHg) or in a context of mixed acidosis with a PaCO2≥ 50 mmHg without possibility of increasing
alveolar ventilation, acute pulmonary edema due to fluid overload despite diuretic therapy leading to severe hypoxemia
requiring oxygen flow rate >5 l/min to maintain SpO2 > 95% or FiO2 > 50% under invasive or noninvasive mechanical
ventilation.
The primary outcome measure is overall survival, measured from randomization (D0) until death, regardless of the cause.
The minimum follow-up duration for each patient will be 60 days. Two interim analyses are planned, blinded to group
allocation. It is expected that there will be 620 subjects in all.
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Discussion: The AKIKI study will be one of the very few large randomized controlled trials evaluating mortality according
to the timing of RRT in critically ill patients with AKI classification stage 3 (KDIGO 2012). Results should help clinicians
decide when to initiate RRT.
Trial registration: ClinicalTrials.gov NCT01932190.
Keywords: Acute kidney injury, Critical care, Renal replacement therapy, Treatment outcomeBackground
Acute kidney injury (AKI) is common in intensive care
unit (ICU) patients [1-3]. Despite progress in symptom-
atic management of AKI and technical advances in renal
replacement therapy (RRT) techniques [4], mortality
remains very high (50 to 60%) [5].
Life-threatening metabolic complications, such as severe
hyperkalemia or overload pulmonary edema responsible
for refractory hypoxemia, are accepted indications for
RRT during AKI [6,7]. In contrast, the accumulation of
uremic or other putative toxins has not been shown to be
a risk factor per se for mortality in AKI and cannot be
used as a reliable indication for RRT. Similarly, severe
gastrointestinal bleeding, a classical complication of AKI,
has almost disappeared during AKI for multiple reasons
(better management of infection and shock, prophylaxis
with inhibitors of gastric acid secretion) [8,9].
Although many authors and experts favor early RRT
[10-12], some hypothesized that too early an RRT ini-
tiation might be harmful [13,14]. Several studies have
recently suggested that delaying or even avoiding RRT
could benefit patients with AKI [15,16]. These uncer-
tainties result in significant practice heterogeneity
[17], making a randomized controlled trial on the tim-
ing of RRT initiation not only ethically justified but
also desired by many clinicians.
To the best of our knowledge, only one such large ran-
domized controlled study is ongoing [18], while another
is due to start in the near future [19].
The Artificial Kidney Initiation in Kidney Injury
(AKIKI) trial is a multicenter randomized controlled trial
comparing the effects of an ‘early’ RRT initiation strategy
with a ‘delayed’ strategy on overall survival of critically ill




The AKIKI study is a prospective, multicenter, open-label,
two-arm randomized study. This study is conducted of pa-
tients receiving invasive mechanical ventilation or cat-
echolamine infusion who have AKI classification stage 3
(KDIGO 2012) [20]. An ‘early’ strategy where RRT is initi-
ated immediately after randomization will be comparedwith a ‘delayed’ strategy, where RRT is initiated only if one
or more ‘severity’ (potentially life-threatening complica-
tions of AKI) criteria occur. These criteria are:
 Oliguria or anuria for more than 72 hours after
randomization,
 Serum urea concentration >40 mmol/l,
 Serum potassium concentration >6 mmol/l,
 Serum potassium concentration >5.5 mmol/l
persisting despite medical treatment (bicarbonate or
glucose-insulin infusion),
 pH <7.15 in a context of pure metabolic acidosis
(PaCO2 < 35 mmHg) or in a context of mixed
acidosis with PaCO2 ≥ 50 mmHg without possibility
of increasing alveolar ventilation,
 Acute pulmonary edema due to fluid overload
leading to severe hypoxemia requiring oxygen flow
rate >5 l/min to maintain SpO2 > 95% or FiO2 > 50%
in patients already undergoing invasive or
noninvasive mechanical ventilation and despite
diuretic therapy.
Patients have to be adequately resuscitated (fluid and
or catecholamine infusion) before potential inclusion;
this is to avoid enrolling patients with rapidly reversible
renal failure and to allow clinician to diagnose acute tubular
necrosis with reasonable accuracy.
Ethical aspects
The study protocol and information forms were ap-
proved by the ethical committee of the French Society of
Intensive Care Medicine (Société de Réanimation de
Langue Française, approval number CE SRLF 13–005)
and by the competent French legal authority (Comité de
Protection des Personnes d’Ile de France VI, Groupe
Hospitalier Pitié Salpêtrière; registration number: 2013-
A00765-40; date of approval 29 May 2013).
Patients are informed orally and provided with a writ-
ten document about the AKIKI study by the investiga-
tors. By French law, written informed consent is not
required, as the standard of care encompasses both
study interventions. As already mentioned, patients or
surrogates are informed about the trial and their right to
refuse participation. If the patient is unable to receive
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decision maker. Patients who are eligible but incapable
of receiving information and for whom a substitute deci-
sion maker is not available may be randomized through
a process of deferred information. They are informed
about participation as soon as their clinical status allows.
Participating intensive care units
A total of 31 French ICUs are participating in the study.
All study sites have medical and paramedical teams
who are experienced in the field of RRT. Because data
in the literature fail to suggest a conclusion on a definite
benefit of one RRT modality over another (intermittent
hemodialysis or continuous techniques), the choice of RRT
modality is left to the team’s discretion depending on their
usual practice. In each study site, RRT prescription and
monitoring are standardized according to the French
national guidelines from panel experts [21].
Study population
Eligible patients are adults (≥18 years) hospitalized in
study ICUs with AKI compatible with the diagnosis of
acute tubular necrosis in a context of ischemic or toxic
aggression and receiving invasive mechanical ventilation
or catecholamine infusion. To be randomized, patients
must fulfill at least one of the three following criteria:
serum creatinine concentration > 354 μmol/l or greater
than three times the baseline creatinine level, anuria
(urine output <100 ml) for more than 12 hours, oliguria
(urine output <0.3 ml/kg/h or <500 ml/day) for more
than 24 hours. These three criteria represent stage 3 of
the KDIGO classification [20].
Patients presenting with one of the accepted indications
for immediate RRT (severity criteria) at baseline
assessment are not included
Other non-inclusion criteria are pre-existing severe
chronic renal failure (defined by creatinine clearance < 30
ml/min); patients already included in the study; patients
with inclusion criteria already present for more than 5
hours (to avoid delayed inclusions); AKI caused by urinary
tract obstruction, renal vessel obstruction, tumor lysis syn-
drome, thrombotic microangiopathy, or acute glomerulopa-
thy; poisoning by a dialyzable agent; Child C liver cirrhosis;
cardiac arrest without awakening; moribund state (patient
likely to die within 24 h); patient having already received
RRT for the current episode of AKI; extracorporeal lung or
circulatory assistance; patients included in another clinical
study of a RRT technique.
All patients treated with invasive mechanical ventilation
or catecholamine infusion with AKI of a lesser degree than
stage 3 of KDIGO classification are screened for eligibility
by the physicians and clinical research nurses around theclock and 7 days a week. Reasons for non-inclusion of all
eligible patients are collected.
Randomization
Eligible patients are consecutively randomly allocated to
one of the two study treatment arms, termed ‘early’ and
‘delayed’ RRT strategies. Randomization and conceal-
ment are achieved using a centralized, secure, computer-
generated, interactive, web-response system accessible
from each study center. The randomization is balanced
by blocks of variable and undisclosed size and stratified
on the center. Before randomization, the presence of the
inclusion criteria and the absence of the non-inclusion
criteria are verified. The randomization day is the study
day zero (D0).
Study interventions
The study protocol and both arms of randomization are
detailed in Figure 1.
When indicated (allocation to early RRT strategy or
occurrence of at least one severity criterion in patients
allocated to delayed RRT strategy), RRT is initiated as
quickly as possible.
As already explained, the choice of RRT modality is
left to the study site’s discretion. Several RRT modalities
can be used in the same patient, according to the attend-
ing physician’s indication. The duration of and interval
between sessions, and device settings and modality of
anticoagulation are left to the investigator’s discretion.
Clinical and biological parameters are monitored, to
detect and treat any complication directly (hyperkalemia,
metabolic acidosis, pulmonary edema) or indirectly (bleed-
ing, infection, thrombosis…) related to AKI or RRT.
‘Early’ RRT strategy
Renal replacement therapy is initiated within 6 hours
after documentation of AKI stage 3 of KDIGO classifica-
tion. The timing of the initiation is recorded and RRT is
continued until criteria for cessation are observed.
‘Delayed’ RRT strategy
Renal replacement therapy is initiated only if one or
more of the severity criteria occur. When required, RRT
is performed with the same modalities and stopped ac-
cording to the same criteria as for the ‘early’ RRT strategy.
Criteria for RRT cessation
Discontinuation of RRT is contemplated if spontaneous
diuresis is ≥500 ml per 24 h, and highly recommended if
diuresis is >1000 ml per 24 h without diuretic adminis-
tration or ≥2000 ml/24 h in patients receiving diuretics.
Cessation of RRT is mandatory if diuresis is present
and serum creatinine level decreases spontaneously.
Critically ill Patients ( 18 years) receiving 
vasoactive agent and/or invasive mechanical 
ventilation  with AKI
AKI stage 3 of KDIGO 2012
AKI did not reach severity criteria
RANDOMIZATION (D0)
Early RRT strategy Delayed RRT strategy
Non-inclusion criteria
RRT as quickly as possible after 
randomization
RRT only if one or more of the 
severity criteria  is observed
Follow-up until D60 at least
Figure 1 Flow chart of the trial. AKI, Acute kidney injury; D60, day 60; KDIGO, kidney disease: improving global outcome; RRT, renal
replacement therapy.
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In the absence of sufficient renal function recovery to
achieve a spontaneous decrease in creatinine level or of
a diuresis greater than 1000 ml/24 h without diuretics
(or greater than 2000 m l/24 h under diuretics), RRT is
resumed.
Authorized treatments (whatever the arm randomization)
Pharmacological prevention of gastrointestinal bleeding
Given the risk factors for digestive bleeding in this popula-
tion (mechanical ventilation or catecholamine infusion in
patients with severe AKI), and in the absence of consensus
on this issue in available guidelines, the protocol recom-
mends the use of a proton pump inhibitor.
Use of diuretics
Diuretics should only be used for the treatment of obvi-
ous sodium and fluid overload in patients whose diuresis
is ≤500 ml per 24 h.
Use of sodium polystyrene sulfonate and isotonic sodium
bicarbonate administration will be left to the clinician’s
discretion.
Fluid therapy, including red blood cell transfusion, is
left to the investigator’s discretion.
The use of hydroxyethyl starch solutions is discouraged.
Data collection and follow-up
At day zero (D0)
Demographic data and medical history, including the
current clinical history with the reason for ICU admission,Simplified Acute Physiology Score III and Sequential Organ
Failure Assessment score will be collected. Potential expos-
ure to nephrotoxic agents (for example, aminoglycosides or
contrast agents) will be documented. Details of treatments
including mechanical ventilation (and its settings), fluid
therapy, catecholamine and anticoagulant administration
are recorded.
Laboratory tests include determination of serum (and
urine if diuresis is present) electrolyte levels, serum glucose
level, urea and creatinine concentration, arterial blood gas
content, and liver and muscle enzyme concentrations. No
renal failure marker identification (such as neutrophil
gelatinase-associated lipocalin) is planned because the clin-
ical usefulness of these markers in routine care has not yet
been demonstrated [19].
Baseline (that is, before occurrence of AKI) serum cre-
atinine concentration will be recorded. Baseline serum cre-
atinine concentration will be determined from either the
results of a measurement in the 12 months preceding the
ICU stay or estimated using the Modification of Diet in
Renal Disease Study Group formula [22]. As a special case,
if serum creatinine concentration was measured more than
12 months before admission, the baseline level will be con-
sidered as the higher of the two estimates (former serum
concentration or that computed using the Modification of
Diet in Renal Disease formula).
From D1 to D28
The same biological data as collected at inclusion will be
recorded according to clinical indication for routine care
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death in the ICU. A search for infection (including
catheter-related infection) or complications related to
RRT or AKI will be carried out according to routine care
procedures. The Sequential Organ Failure Assessment
score will also be calculated at D3, D7, D14, D21, and D28.
At D60
Vital status (alive or dead) and duration of hospital and
ICU stay will be recorded. Details and timings of patient
follow-up are summarized in Table 1.
After D60
Vital status and dialysis dependency will regularly be up-
dated for each patient until the end of the study (that is,
day 60 after inclusion of the last patient).
Organization of the trial
Funding and support
The AKIKI trial is promoted by the Assistance Publique -
Hôpitaux de Paris and supported by a grant from the
French Ministry of Health (Programme Hospitalier de
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or acute kidney injury
X
Total cost of renal
replacement therapy
X
Duration of stay in intensive
care unit or hospital
X X
Alive or dead status X XCoordination and implementation of the trial
Each medical and paramedical team in the 31 participating
ICUs were trained in the protocol and data collection using
an electronic case-record form during formal meetings
prior to screening and inclusion. The electronic case-record
form was developed with CleanWEBTM, a centralized, se-
cure, interactive, web-response system accessible from each
study center, provided and managed by Telemedicine
Technologies.
Local physicians and clinical research assistants in
each participating ICU are responsible for daily screen-
ing and inclusion of patients, compliance with protocol,
availability of data requested for the trial and comple-
tion of the electronic case-record form. In accordance
with French law, the electronic case-record form and
database were validated by appropriate committees
(Comité Consultatif sur le Traitement de l’Information
en matière de Recherche dans le domaine de la Santé;
Commission Nationale de l’Informatique et des Libertés).
Interim analysis
Two interim analyses by an independent data safety and
monitoring board are planned after the occurrence of 90
and 180 deaths. The data safety and monitoring board
will be blinded to allocation of groups and may decide
premature termination of the study. The board consists
of one methodologist, one nephrologist, and two intensi-
vists. Data are blindly analyzed but unblinding is pos-
sible on request of the data safety and monitoring board.
An extraordinary meeting may be requested by the prin-
cipal investigator or the methodologist, in the case of
unexpected events that might affect continuation of the
protocol.
Blinding
Given the nature of the interventions, physicians, nurses,
and patients cannot be blinded for the randomized inter-
ventions. Lack of blinding is, however, partially counter-
balanced by the objective nature of the primary outcome




The primary endpoint measure is the overall survival.
Overall survival is measured from the randomization date
(D0) until death, regardless of the cause. For patients dis-
charged alive, information on the primary endpoint meas-
ure will be collected by a telephone call to the patient’s
home or by a conversation with the physician in charge, if
the patient is still in a care facility. The minimum follow-up
duration for each patient will be 60 days. The status (alive
or dead) of patients lost to follow-up before the planned
follow-up duration will be checked by obtaining their birth
Table 2 Number of deaths, expected number of subjects,
and significance level of testing at each preplanned







Single analysis 263 546 5%
Interim analyses:
First analysis 90 187 0.15%
Second analysis 180 373 1.81%
Final analysis 270 560* 4.37%
*To take into account a potential loss to follow-up of about 10%, it is planned
to include a total of 620 subjects in the study.
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ment) from the City Hall of their city of birth (French law
allows anyone to ask for such certificate). Patients for
whom vital status remains unknown at D60 (a rare occur-
rence) or who are still alive at the end of their follow-up
period will be censored at the last date to which their health
status has been documented.
Secondary endpoints
Secondary endpoint measures are the percentage of pa-
tients receiving RRT at least once in the ‘delayed’ RRT
strategy arm (compared with the 100% of patients in the
‘early’ strategy); the number of RRT sessions per patient
(analyzing living and dead patients separately); the time
between randomization (D0) and RRT initiation; the
time between observation of at least one of the severity
criteria (which mandates RRT in the delayed strategy)
and RRT; the time to RRT weaning; the number of days
alive without RRT (between D0 and up to D28); the time
between D0 and the first RRT and between the last RRT
and D60; the number of dialysis catheter-free days be-
tween D0 and D28; the rate of adverse events potentially
related to AKI or RRT (including: (a) hemorrhage requir-
ing red blood cell transfusion or surgical procedure, (b)
thrombocytopenia (<100,000 platelets/mm3), (c) throm-
bosis of a large venous axis diagnosed by Doppler ultra-
sonography, (d) hypokalemia (defined as serum potassium
concentration < 3 mmol/l), (e) hypophosphatemia (defined
as a serum phosphate concentration < 0.6 mmol/l), (f)
hyperkalemia (>6.5 mmol/l), (g) cardiac rhythm disorders
(ventricular tachycardia, ventricular fibrillation, torsades
de pointes or a new episode of atrial fibrillation requiring
medical treatment or external electric counter shock);
the number of days alive without mechanical ventilation
between D0 and D28; the rate of nosocomial infections
(bloodstream, lung and catheters and unexplained
bacteremia or fungemia); the number of days alive without
vasopressors between D0 and D28; the progression of
organ failures assessed using the Sequential Organ Failure
Assessment score; the duration of stay in the ICU and in
hospital generally (limited to D60); the survival rate at
D28; the proportion of patients with treatment limitations
(withholding or withdrawal); and the total cost of RRT-
related consumables between D0 and D28 (catheters, solu-
tions for RRT, membranes, and circuitry).
Statistical methods
Sample size calculation
The aim of this study is to demonstrate a difference in
outcome between two therapeutic strategies. Our pri-
mary hypothesis is that the ‘delayed’ RRT strategy
might be beneficial to patients with AKI. The sample
size calculation is based on the primary endpoint measure:
overall survival.The expected mortality of patients included in this type
of studies may be estimated at around 55%, according to
the literature [2,24-26]. Indirect evidence from retrospective
studies [13,16] suggests that a 15% decrease in mortality
can be expected with delayed indication for RRT (the rea-
sons for this are explained in the discussion section).
To demonstrate a 14% decrease in mortality (from 55
to 41%, corresponding to a relative reduction in the risk
of mortality by 1.5 in the ‘delayed’ RRT strategy arm, as-
suming exponential survival), a total of 546 subjects
(273 per group) should be randomized to provide a
study power of 90%, with an alpha risk of 5% between
both treatments (bilateral formulation).
Interim analyses
Two blind and independent interim analyses (making a
total of three analyses) are planned in this study. Interim
analyses will be conducted after the observation of 90
and 180 deaths.
To maintain an overall type I error rate of 5%, the sig-
nificance level of each analysis is adjusted, using the
O’Brien & Fleming approach of group sequential analysis
[27]. To maintain a power of 90%, this approach provides
an increase in the planned number of subjects required
for a single analysis; that is, 560 subjects instead of 546.
Table 2 describes the number of events required for each
analysis, the planned number of subjects and the signifi-
cance levels applied for testing (with due correction).
Total planned sample size
To take into account a potential loss to follow-up of
about 10%, it is expected that a total of 620 subjects will
be enrolled in this study.
Methodology of the statistical analysis
A patient follow-up chart will describe the number of
eligible patients and the number of patients actually in-
cluded (total and per arm).
For each group and at each assessment date, qualitative
variables will be described as number and percentage, and
quantitative variables as number, mean, and standard
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will be presented as median and interquartile range
(25th percentile to 75th percentile).
Analysis of the primary endpoint
The overall survival (primary endpoint), estimated using
the Kaplan-Meier method, will be analyzed in the
intention-to-treat population.
Regarding the comparison of the survival between the
‘early’ and ‘delayed’ arms, the assumptions are: H0: Rela-
tive risk (RR) = 1 and H1: RR ≠ 1. This comparison will
be based on the log-rank test.
For the first and second interim analyses, this test will
be performed at an alpha risk of 0.15% and 1.81%, respect-
ively. If the test is significant, the null hypothesis will be
rejected and it will be concluded that there is a difference
in overall survival between strategies. The inclusion of pa-
tients in the study will then be terminated early.
If the inclusion has not been terminated after the two
planned interim analyses, the final analysis will be per-
formed when 620 patients will be included, after the 60
days of follow-up of the last included patient. This ana-
lysis will be performed at an alpha risk of 4.37%.
All these tests will be performed with a bilateral
formulation.
Other analyses
Categorical variables will be compared using the χ2 or
Fisher’s test, as appropriate. Continuous variables will be
compared using Student’s t test or the Wilcoxon test, as
appropriate.
The analysis of the overall survival will be adjusted for
important stratification and prognostic factors using a
multivariate analysis (Cox model). The adjustment fac-
tors will include: baseline Simplified Acute Physiology
Score III, RRT technique used, treatment with catechol-
amines at baseline, mechanical ventilation at baseline,
septic shock at baseline, time between admission in ICU
and AKI development (less than, greater than, or equal
to 7 days).
All secondary analyses will be conducted at the bilateral
alpha risk of 5%.
Analyses will be performed using R software (R Founda-
tion for Statistical Computing, Vienna, Austria) version
2.14 or later, or SAS version 9.2.
Discussion
When to start RRT is one of the key questions during
severe AKI in critically ill patients. Recent expert panel
opinions considered that answering this question is one
of the top priorities in research on AKI [7].
Life-threatening hyperkalemia, acute overload pulmonary
edema generating severe hypoxemia, and uremic com-
plications (pericarditis and encephalopathy) are theonly indisputable emergency RRT criteria [6,7]. Apart
from these situations, there is considerable debate on
the potential merits of an early RRT strategy, which
would allow better immediate control of metabolic dis-
orders but expose patients to potential adverse effects, in
particular complications associated with catheter and
extracorporeal circulation and of a delayed strategy that
would minimize these risks at the price of more severe or
prolonged metabolic disorders.
Indeed, placing an unstable patient with septic shock
(or other circulatory compromise) on RRT is not devoid
of risk, even in experienced teams [28]. By the same
view, delaying RRT for several hours or even days may
allow RRT to be initiated in a stabilized patient and, in
the best case scenario, may allow spontaneous recovery
of renal function, avoiding unnecessary RRT. However,
such an approach entails increased risk of metabolic or
unknown complications.
To the best of our knowledge, apart from this study,
only two prospective randomized studies are actually
addressing [18] or plan to address this issue [19], with
mortality as the main endpoint measure. Both studies
share the premise that early RRT would be better than
late. In contrast, the AKIKI study is the only one that
tests a completely opposite hypothesis.
All three studies seem to share similar criteria for early
initiation: RRT is started in the few hours following obser-
vation of severe AKI in patients who are adequately resus-
citated to discard the hypothesis of rapidly reversible renal
failure.
Unlike the two other studies, we think that the risk asso-
ciated with early RRT may exceed that related to delayed
RRT. Our hypothesis of a reduction of mortality with a de-
layed strategy is based on an analysis of the literature that
shows that patients with the so-called usual criteria for
RRT (but without obvious life-threatening electrolyte or
fluid-balance abnormality) may have an excellent prognosis,
with mortality rates between 26 and 31% [15,16].
We hypothesize that patients in the delayed RRT strat-
egy arm may have a chance of recovering acceptable
renal function, obviating the need for RRT and that the
others may have RRT performed in better conditions.Trial status
Enrollment is ongoing, having started on September
2013. The first interim analysis was conducted in August
2014, and the data safety and monitoring board recom-
mended that the study be continued. On December 14,
2014, 322 patients were included in the trial. Enrollment
is expected to be completed in March 2016.
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